Cantor Fitzgerald Comments on Cyclerion Therapeutics, Inc.’s FY2021 Earnings (NASDAQ:CYCN)

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) – Analysts at Cantor Fitzgerald lifted their FY2021 earnings per share estimates for Cyclerion Therapeutics in a report issued on Tuesday, November 23rd. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will earn ($1.36) per share for the year, up from their previous forecast of ($1.70). Cantor Fitzgerald currently has a “Overweight” rating and a $7.00 target price on the stock. Cantor Fitzgerald also issued estimates for Cyclerion Therapeutics’ FY2022 earnings at ($1.18) EPS.

Cyclerion Therapeutics (NASDAQ:CYCN) last posted its quarterly earnings data on Tuesday, November 9th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.09. Cyclerion Therapeutics had a negative return on equity of 104.73% and a negative net margin of 1,696.27%.

A number of other research analysts also recently issued reports on the company. Truist Securities started coverage on Cyclerion Therapeutics in a report on Wednesday, October 20th. They set a “buy” rating and a $14.00 price objective for the company. Truist started coverage on Cyclerion Therapeutics in a research report on Wednesday, October 20th. They set a “buy” rating and a $14.00 price target for the company.

NASDAQ:CYCN opened at $2.65 on Thursday. Cyclerion Therapeutics has a 52-week low of $2.08 and a 52-week high of $6.90. The stock has a 50-day simple moving average of $2.81 and a 200 day simple moving average of $3.16.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Morgan Stanley lifted its position in shares of Cyclerion Therapeutics by 6.2% in the third quarter. Morgan Stanley now owns 74,508 shares of the company’s stock valued at $229,000 after buying an additional 4,353 shares during the last quarter. XTX Topco Ltd lifted its position in shares of Cyclerion Therapeutics by 34.4% in the second quarter. XTX Topco Ltd now owns 17,968 shares of the company’s stock valued at $70,000 after buying an additional 4,603 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Cyclerion Therapeutics by 20.9% in the third quarter. Goldman Sachs Group Inc. now owns 43,903 shares of the company’s stock valued at $135,000 after buying an additional 7,586 shares during the last quarter. Barclays PLC lifted its position in shares of Cyclerion Therapeutics by 159.0% in the first quarter. Barclays PLC now owns 18,516 shares of the company’s stock valued at $52,000 after buying an additional 11,367 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in shares of Cyclerion Therapeutics in the third quarter valued at approximately $51,000. 65.21% of the stock is owned by hedge funds and other institutional investors.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators, a small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate (cGMP).

Further Reading: What strategies should day traders use to execute a trade?

Earnings History and Estimates for Cyclerion Therapeutics (NASDAQ:CYCN)

Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.